ELI LILLY & Co
LLY evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $1.00T
- Lead Asset:
- Basaglar (Approved)
What it means
What to watch
Prepared research question
What matters most for LLY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LLY
Eli Lilly & Co is a global pharmaceutical company focused on metabolic, oncology, and immunology therapies, with its recent growth driven by tirzepatide-based products Mounjaro and Zepbound.
Key risk: Pricing pressure on key products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 26 pipeline candidates · 403 clinical trials · 6 catalysts · 19 FDA decisions for ELI LILLY & Co.
Eli Lilly & Co is a global pharmaceutical company focused on metabolic, oncology, and immunology therapies, with its recent growth driven by tirzepatide-based products Mounjaro and Zepbound.
- Revenue increased 45% to $65 billion in 2025 under CEO Dave Ricks [sec · filed 2026-03-20].
- As of 2026-06-30, cash & equivalents were $8,950.0M, total revenue $22,974.0M, net income $7,095.0M, shareholders' equity $33,879.0M, and total debt $54,908.0M [sec].
- Revenue growth for the three and six months ended June 30, 2026 was driven primarily by increased volume from Mounjaro and Zepbound, partially offset by lower realized prices [sec_mda · as of 2026-08-05].
- The company obtained FDA approvals for Omvoh for Crohn's disease and Inluriyo in 2025 [sec · filed 2026-03-20].
- A Phase 3 study of oral orforglipron in Chinese adults with obesity or overweight is scheduled to start on 2026-12-01 [catalyst].
What works
- Strong revenue growth driven by tirzepatide products Mounjaro and Zepbound, with company revenue increasing 45% to $65 billion in 2025 [sec · filed 2026-03-20].
- Broad pipeline with positive clinical data in more than 25 Phase 3 trials in 2025 [sec · filed 2026-03-20].
- Recent FDA approvals for Omvoh (Crohn's disease) and Inluriyo expand the commercial portfolio [sec · filed 2026-03-20].
What to weigh
- Lower realized prices for Mounjaro and Zepbound partially offset volume-driven revenue growth [sec_mda · as of 2026-08-05].
- Total debt of $54,908.0M as of 2026-06-30 significantly exceeds cash & equivalents of $8,950.0M [sec].
- Higher acquired IPR&D charges, asset impairment, and restructuring costs weighed on net income in the first half of 2026 [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Revenue growth driven by Mounjaro and Zepbound volume
“The increased volume and the lower realized prices during the three and six months ended June 30, 2026 were primarily driven by Mounjaro and Zepbound.”
SEC MD&A · August 5, 2026
2025 revenue increased 45% to $65 billion
“Increased company revenue by 45% to $65 billion”
SEC filings · March 20, 2026
Positive clinical data in more than 25 Phase 3 trials in 2025
“Lilly generated positive clinical data in more than 25 Phase 3 trials”
SEC filings · March 20, 2026
FDA approvals for Omvoh and Inluriyo in 2025
“Obtained FDA approvals for Omvoh for Crohn's disease, Inluriyo”
SEC filings · March 20, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Start: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities — Initiation of a Phase 3 trial for orforglipron in obesity in China, expanding the geographic reach of the pipeline.
- 2032-11-30 · Patent_Expiry · BARICITINIB — Patent_Expiry: NDA207924 — Patent expiry for baricitinib, which could lead to generic competition.
- 2034-06-11 · Patent_Expiry · EMPAGLIFLOZIN — Patent_Expiry: NDA204629 — Patent expiry for empagliflozin, potentially opening the market to generics.
- 2037-09-26 · Patent_Expiry · ORFORGLIPRON CALCIUM — Patent_Expiry: NDA220934 — Patent expiry for orforglipron calcium, a key pipeline candidate.
- 2039-07-11 · Patent_Expiry · IMLUNESTRANT TOSYLATE — Patent_Expiry: NDA218881 — Patent expiry for imlunestrant tosylate, an oncology asset.
- 2041-12-30 · Patent_Expiry · TIRZEPATIDE — Patent_Expiry: NDA215866 — Patent expiry for tirzepatide, the active ingredient in Mounjaro and Zepbound.
Risks & what to watch (3)›
Key risks
- Pricing pressure on key products — Lower realized prices for Mounjaro and Zepbound partially offset volume gains [sec_mda · as of 2026-08-05].
- High debt levels — Total debt of $54,908.0M as of 2026-06-30, far exceeding cash of $8,950.0M [sec].
- Patent expirations on key drugs — Baricitinib patent expires 2032-11-30, empagliflozin 2034-06-11, tirzepatide 2041-12-30 [catalyst].
What to watch
- Phase 3 start of oral orforglipron for obesity in China on 2026-12-01 [catalyst].
- New data presentations at the EASD annual meeting in September 2026 across the cardiometabolic portfolio [news · published 2026-09-15].
- Ongoing clinical collaboration evaluating narmafotinib plus olomorasib in KRAS G12C-mutant NSCLC [news · published 2026-08-04].
- Revenue and volume trends for Mounjaro and Zepbound amid pricing dynamics [sec_mda · as of 2026-08-05].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run ELI LILLY & Co through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ELI LILLY & Co facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.20 · 0% dilution
Lead: Approved
26 candidates
6 upcoming, next in ~48d
0 buys · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.9%
- Days to cover
- 2.5
- Shares short
- 7,862,175
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LLY short interestGovernance
Frequently asked questions
What is the AI investment thesis for ELI LILLY & Co?
Eli Lilly & Co is a global pharmaceutical company focused on metabolic, oncology, and immunology therapies, with its recent growth driven by tirzepatide-based products Mounjaro and Zepbound.
What is ELI LILLY & Co's lead drug candidate?
ELI LILLY & Co's most advanced tracked candidate is Basaglar (Approved) for for the treatment of diabetes..
What is ELI LILLY & Co's next catalyst?
ELI LILLY & Co's next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities" — expected December 1, 2026.
Who is the CEO of ELI LILLY & Co?
Mr. David A. Ricks is the chief executive officer of ELI LILLY & Co (LLY).
Where is ELI LILLY & Co headquartered?
ELI LILLY & Co (LLY) is headquartered in Indianapolis, IN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.